Objective
to determine whether shortening the duration of P2Y12 inhibitor therapy (clopidogrel or prasugrel) can reduce the risk of bleeding without increasing the risk of major adverse cardiovascular events (MACE) following coronary stenting in patients with atrial fibrillation (AF) treated with NOAC (apixaban)
Study
prospective, multicentre, randomised, open label
Population
patients with coronary artery disease indicated for PCI using drug eluting stent (DES) with non-valvular AF CHADSVASCâ¥1 age 20 years or older
Endpoints
primary endpoint incidence of any bleeding events within 12 months PCI defined via TIMI and BARC criteria. Secondary endpoints composite all-cause mortality, MI, stroke, systemic embolisation, or bleeding with BARC 3 or higher
Conclusion
triple therapy for 1 month was comparable to triple therapy for 6 months. Interpretation is limited as enrolment was prematurely terminated and statistical power to detect differences between treatment arms was low.
Hoshi et al. EuroIntervention. 2020;16:164-72
